European Patent for Tesofensine Treating Hypothalamic Obesity
Summary
EPO published patent application EP4138830A1 by Saniona A/S covering the use of tesofensine for treating hypothalamic obesity. The patent is classified under A61K 31/46, A61K 45/06, A61P 3/04, and designates 38 European states including DE, FR, GB, IT, ES, NL, SE, and others. Inventors include DREJER Jørgen, KROGSGAARD Kim, and EDBERG Berit.
What changed
EPO published patent application EP4138830A1 for Saniona A/S covering tesofensine formulations and methods for treating hypothalamic obesity. The patent designates 38 European contracting states including major markets such as Germany, France, United Kingdom, Italy, Spain, and the Netherlands.
For pharmaceutical companies developing obesity treatments, this patent establishes IP protection for tesofensine in the hypothalamic obesity indication across major European markets. Saniona gains exclusive rights to this therapeutic use, which may impact competitive positioning in the European obesity drug market.
What to do next
- Review EPO register for patent status and coverage scope
- Monitor for potential licensing opportunities
- Assess freedom-to-operate implications in designated states
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TREATMENT OF HYPOTHALAMIC OBESITY WITH TESOFENSINE
Publication EP4138830A1 Kind: A1 Apr 01, 2026
Applicants
Saniona A/S
Inventors
DREJER, Jørgen, KROGSGAARD, Kim, EDSBERG, Berit
IPC Classifications
A61K 31/46 20060101AFI20211029BHEP A61K 45/06 20060101ALI20211029BHEP A61P 3/04 20060101ALI20211029BHEP A61K 31/138 20060101ALI20211029BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.